Metastatic breast cancer global perspectives by clinical experts
Practice changes and horizon openings from ESMO 2019 and beyond: immunotherapy, PARP inhibitors, AKT drugs, Survival data with CDK4/6 inhibitors.
Faculty Co-Chair
Nadia Harbeck MD, PhD
Ludwig-Maximilians-University of Munich LMU – Breast Center, Germany
Faculty Co-Chair
Mohammad Jahanzeb, MD, FACP
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, USA
Look Inside This Report
Download a sample of the highligts report and start discovering the insights.
Key Topics
- The extent to which scientific experts have consensus on the best ways of treating triple-negative breast cancer: immunotherapy, PARP inhibitors, AKT drugs
- Immunotherapy – expert recommendations about the benefits and the place of this treatment option
- Cytotoxic chemotherapy – expert opinions around the future use of this type of therapy
- The latest CDK4/6 inhibitors survival data: experts discuss to what extent CDK4/6 inhibitors are alike and to what extent these data will change the treatment algorithm
- How to appropriately maximize the benefits of targeted therapies in breast cancer on the basis of reported data that are practice-changing, as well as hypothesis generating for future trials
- Expert opinions on how new reported data in HER2+ breast cancer will change its treatment
Expert Faculty
Lisa A. Carey, MD
University of North Carolina at Chapel Hill, United States
Javier Cortes, MD
Vall d´Hebron Institute of Oncology (VHIO), Spain
Alessandra Gennari, MD, PhD
University of Eastern Piedmont, Italy
Joyce O’Shaughnessy, MD
Texas Oncology-Baylor Charles A. Sammons Cancer Center, USA
Per Lønning, MD, PhD
University of Bergen, Norway
Peter Schmid, MD, PhD
Barts Cancer Institute, United Kingdom
